Buysiders on board with BMS’s plans for Otezla cash

A trio of biotech investors agree that paying down debt over investing in R&D is the best use of the $13.4 billion in cash Bristol-Myers will gain from the sale of Otezla apremilast to Amgen. The trade-off is buttressed by the chunk of innovation

Read the full 446 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE